"The DECO Study: A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) in the Treatment of Localised Resectable Cancer of the Oesophagus."
Primary Sponsor
Related Post
5 December, 2024
Extended follow-up of TROG 99.03 lymphoma trial published
5 December 2024: Study shows huge improvement in progression-free
28 November, 2024
Meet TROG President: A/Prof Puma Sandaresan
28 November 2024: In this Q&A, TROG President A/Prof
